The State of California has launched a legal challenge against two major pro-life organizations, alleging they used deceptive marketing tactics to promote a medical treatment known as “abortion pill reversal.”
California Attorney General Rob Bonta filed the lawsuit in the Alameda County Superior Court against Ohio-based Heartbeat International, Inc. and California-based RealOptions, which operates five pregnancy resource clinics under the name RealOptions Obria Medical Clinics. The state’s civil complaint accuses the organizations of violating California’s Business and Professions Code by spreading “false and misleading statements” and engaging in unlawful, unfair, and fraudulent business practices.
At the center of the lawsuit is the marketing of a protocol that claims high doses of the hormone progesterone can counteract the effects of mifepristone, the first medication taken during a standard two-drug medical abortion. Heartbeat International manages the Abortion Pill Rescue Network and a 24-hour hotline, which connect individuals with local providers willing to administer the progesterone treatment.
According to the state’s legal complaint, “not a single credibly designed medical study has verified” the defendants’ assertions that medication abortions can be reversed. The state argues that the pro-life groups rely on a 2012 case series and a 2018 report co-authored by doctors associated with the organizations.
The lawsuit claims these publications are fundamentally flawed, citing a “lack of random sampling, the absence of controls or a comparison group, and heterogeneity of subjects.” The state also points out that three major medical journals rejected the 2018 report before it was published in Issues in Law & Medicine, a journal sponsored by anti-abortion organizations.
Furthermore, California prosecutors highlight a 2019 randomized clinical study at the University of California, Davis, which attempted to test the safety and efficacy of the reversal protocol. That study had to be halted early due to acute “safety concerns” after three of the 12 enrolled participants experienced severe bleeding that required ambulance transport to an emergency department.
The lawsuit alleges that the defendants intentionally omit these risks from their marketing, hotlines, training kits, and patient consent forms. On their websites, both Heartbeat International and RealOptions advertise that initial studies show the reversal protocol has a “64-68% success rate” and that the process is “effective.” Heartbeat International also claims that “thousands of lives have been saved” through the network.
The state maintains that these numbers are based on speculation rather than sound science, particularly because the statistics lump together pregnancies at various gestational ages and fail to account for individuals who might have maintained their pregnancies simply by choosing not to take the second abortion pill, misoprostol, without any hormonal intervention. The complaint also challenges the organizations’ advertisements suggesting the treatment remains safe and effective after the recommended 72-hour window, or following the use of alternative abortion medications like methotrexate.
Major medical entities, including the American College of Obstetricians and Gynecologists (ACOG) and the American Medical Association (AMA), are cited in the complaint as supporting the state’s position that the reversal treatments do not meet clinical standards and are not supported by reliable scientific evidence.
Through this lawsuit, Attorney General Bonta is seeking a permanent injunction to prevent Heartbeat International and RealOptions from making any further unverified claims regarding the efficacy and safety of the protocol. Additionally, the state is asking the court to assess civil penalties of up to $2,500 for each individual violation of the state’s false advertising and unfair competition laws.
READ: FBI: New Arrests In Washington And Missouri Expand White House UFC Attack Probe
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
